{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.6","upperLimit":"26.6","value":"21.1"},{"groupId":"OG001","lowerLimit":"5.5","upperLimit":"13.3","value":"9.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"213"}],"units":"Participants"}],"description":"ORR was the best confirmed overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Imlunestrant 400 mg orally once daily on Days 1 to 28 of a 28-day cycle, plus Abemaciclib 150 mg orally twice daily on Days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation was met.","id":"OG000","title":"Arm C: Imlunestrant + Abemaciclib"},{"description":"Participants received Imlunestrant 400 milligrams (mg) orally once daily on days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation were met.","id":"OG001","title":"Arm A: Imlunestrant"}],"paramType":"NUMBER","populationDescription":"All participants who were randomly assigned to either arm A or arm C concurrently.","reportingStatus":"POSTED","timeFrame":"Randomization until measured progressive disease (up to 26 months)","title":"Percentage of Participants With Investigator-assessed Objective Response Rate (ORR) (Between Arm C and Arm A)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}